Susquehanna International Group
TPTX

Susquehanna International Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Susquehanna International Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31,218
Closed -$2.35M – 14792
2022
Q2 		$2.35M Sell
31,218
-23,442
-43% -$1.04M ﹤0.01% 4574
2022
Q1 		$1.47M Sell
54,660
-17,160
-24% -$577K ﹤0.01% 6190
2021
Q4 		$3.43M Buy
71,820
+45,234
+170% +$2.02M ﹤0.01% 4418
2021
Q3 		$1.77M Sell
26,586
-454
-2% -$32.3K ﹤0.01% 6108
2021
Q2 		$2.11M Buy
27,040
+9,871
+57% +$729K ﹤0.01% 5798
2021
Q1 		$1.62M Sell
17,169
-9,953
-37% -$1.18M ﹤0.01% 6434
2020
Q4 		$3.31M Buy
27,122
+4,770
+21% +$523K ﹤0.01% 4146
2020
Q3 		$1.95M Buy
22,352
+4,727
+27% +$329K ﹤0.01% 4668
2020
Q2 		$1.14M Sell
17,625
-40,580
-70% -$2.34M ﹤0.01% 5618
2020
Q1 		$2.6M Buy
58,205
+50,810
+687% +$2.7M ﹤0.01% 3518
2019
Q4 		$461K Buy
+7,395
New +$352K ﹤0.01% 7150

Susquehanna International Group's TPTX Position: Q3 2022 in Review

Susquehanna International Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 31,218 shares — an estimated $2.35M sold.

Susquehanna International Group first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $3.43M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Susquehanna International Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Susquehanna International Group sold 31,218 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.35M.
  • Susquehanna International Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Susquehanna International Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.43M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.